Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

JHL Biotech Proposes Voluntary Delisting from Taiwan Exchange

publication date: Dec 21, 2017

JHL Biotech is planning a voluntary delisting from the Taiwan stock exchange. The biosimilar company, which has a $419 million market capitalization, operates in Taiwan and Wuhan, China. The proposed delisting allows shareholders to hold on to their shares while the company is private, if they choose to do so. Following the delisting, JHL anticipates new sources of funding, most likely including an IPO on a foreign exchange. In 2012, JHL was founded in Taiwan by veterans of Genentech and Amgen with the goal of producing affordable, effective biosimilar drugs. More details....

Stock Symbol: (TPEx: 6540)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.